Form 4: TransMedics Director Exercises Options and Sells Shares Under Pre-Arranged Plan

TransMedics Group, Inc. Director Edward M. Basile exercised stock options and subsequently sold 5,000 shares of common stock for approximately $126.45 per share, reducing his direct beneficial ownership to 2,866 shares.

Summary

• Edward M. Basile, a Director of TransMedics Group, Inc. (TMDX), reported changes in his beneficial ownership of company securities.
• On May 27, 2025, Mr. Basile acquired 5,000 shares of Common Stock through the exercise of a stock option at an exercise price of $0.70 per share.
• Concurrently, on May 27, 2025, Mr. Basile sold 5,000 shares of Common Stock at a price of $126.45 per share.
• These transactions were conducted pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following these transactions, Mr. Basile's direct beneficial ownership of Common Stock decreased from 7,866 shares to 2,866 shares.
• He still beneficially owns 8,285 derivative securities (stock options) with an exercise price of $0.70, which are fully vested and expire on February 16, 2026.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the sale of shares by a director can be viewed negatively, the fact that it was executed under a pre-arranged Rule 10b5-1 plan mitigates concerns about it being a reaction to adverse undisclosed information. The exercise of options also indicates value realization.

Positives

• The exercise of stock options indicates that the options held value, allowing the director to acquire shares at a significantly lower price than the market sale price.
• The transaction was executed under a Rule 10b5-1 plan, which suggests a pre-scheduled and systematic approach to share disposition, rather than a reactive sale based on new, undisclosed information.

Negatives

• A director selling shares, even under a pre-arranged plan, can sometimes be perceived negatively by the market as it reduces insider ownership.
• The direct beneficial ownership of common stock by Mr. Basile decreased by 5,000 shares following these transactions.

Risks

• Market perception of insider sales, even if pre-planned, could lead to short-term negative sentiment or scrutiny regarding the company's future prospects.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape. It reflects an individual director's personal financial planning.

Stakeholder Impact

• Shareholders may interpret the director's sale as a signal, though the pre-planned nature under Rule 10b5-1 suggests it is for personal financial management rather than a reflection of company performance.

Key Dates

Recommendation

Keywords

TransMedics Group, TMDX, SEC Form 4, Insider Trading, Stock Option Exercise, Share Sale, Edward Basile, Director, Beneficial Ownership, Rule 10b5-1